Celularity Inc
For the period ended Mar 31, 2025. Filed Aug 29, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed Aug 29, 2025
CELU$0.71-6.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flow from operating activities: | ||
| Net loss | $(19,754) | $(22,013) |
| Adjustments to reconcile net loss to net cash used in operations: | ||
| Depreciation and amortization | 1,834 | 2,156 |
| Non cash lease expense | 32 | 45 |
| Provision for inventory obsolescence | (123) | (45) |
| Provision for credit losses | (61) | 201 |
| Change in fair value of warrant liabilities | (242) | 8,875 |
| Loss on issuance of common stock to Yorkville in connection with the Side Letter | 149 | – |
| Loss on issuance of common stock in connection with the settlement of debt | 51 | – |
| Stock-based compensation expense | 2,637 | 2,966 |
| Issuance of common stock to Palantir as consideration for settlement agreement | – | 50 |
| Issuance of common stock relating to Yorkville for debt extension and SEPA commitment fee | – | 317 |
| Loss on extinguishment of debt | 5,736 | 3,908 |
| Change in fair value of debt | 12 | (81) |
| Non cash interest expense | 2,451 | 1,148 |
| Other, net | – | 181 |
| Changes in assets and liabilities: | ||
| Accounts receivable | (1,350) | (3,924) |
| Inventory | 2,550 | 3,181 |
| Prepaid expenses and other assets | 251 | 294 |
| Accounts payable | 17 | (1,172) |
| Accrued expenses and other liabilities | 2,709 | 1,171 |
| Accrued R&D software | – | (1,800) |
| Lease liabilities — operating | 83 | 88 |
| Deferred revenue | 25 | 51 |
| Net cash used in operating activities | (2,993) | (4,403) |
| Cash flow from investing activities: | ||
| Capital expenditures | – | (39) |
| Net cash used in investing activities | – | (39) |
| Cash flow from financing activities: | ||
| Proceeds from warrants and short-term debt — related parties | – | 15,000 |
| Proceeds from issuance of common stock in connection with a warrant inducement | 2,460 | – |
| Repayments of short-term debt — unaffiliated | – | (17,374) |
| Proceeds from issuance of short-term debt — unaffiliated | – | 2,993 |
| Payment of SEPA commitment fee | – | (25) |
| Repayments of short-term debt — related parties | (42) | (10) |
| Proceeds from PIPE Offering, net of offering costs | – | 6,000 |
| Tax withholding on vesting of restricted stock units | (98) | (357) |
| Net cash provided by financing activities | 2,320 | 6,227 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (673) | 1,785 |
| Cash, cash equivalents and restricted cash at beginning of period | 10,977 | 10,163 |
| Cash, cash equivalents and restricted cash at end of period | $10,304 | $11,948 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $– | $– |
| Cash paid for income taxes | $– | $– |
| Supplemental non-cash investing and financing activities: | ||
| Property and equipment included in accounts payable and accrued expenses | $– | $(11) |
| Contingent consideration reclassified to accrued expenses and other current liabilities | $650 | $– |
| Deemed dividend relating to inducement of Dragasac warrants | $64 | $– |
| Issuance and modification of C.V. Starr warrants in connection with forbearance | $– | $51 |
| Issuance of RWI warrants in connection with forbearance | $– | $1,223 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.